Home > Healthcare > Medical Devices > Therapeutic Devices > Diabetic Retinopathy Market
Diabetic Retinopathy Market Size was valued at USD 8 billion in 2018 and is expected to witness 6.9% CAGR from 2019 to 2025.
Favourable reimbursement policies available for ophthalmologic surgeries should positively influence diabetic retinopathy market growth. Diabetic retinopathy is a chronic condition that affects eyes and leads to blindness in elderly people. Laser surgery not only helps in retaining eye sight but also, prevents from further damage caused by proliferative diabetic retinopathy. Since there have been technological interventions in these surgeries, elderly people and population in emerging economies face affordability issues due to hike in price of surgeries. Therefore, insurance providers such as Medicaid and Medicare implement several policies to reduce the procedural costs that proves beneficial for industry growth.
Report Attribute | Details |
---|---|
Base Year: | 2018 |
Diabetic Retinopathy Market Size in 2018: | 8 Billion (USD) |
Forecast Period: | 2019 to 2025 |
Forecast Period 2019 to 2025 CAGR: | 6.9% |
2025 Value Projection: | 12 Billion (USD) |
Historical Data for: | 2014 to 2018 |
No. of Pages: | 120 |
Tables, Charts & Figures: | 63 |
Segments covered: | Type, Age Group, Management, Distribution Channel and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Technological advancements in the ophthalmic surgical and diagnostic instruments will foster diabetic retinopathy market growth during forecast years. Optical coherence tomography and other technologically upgraded devices utilized in diagnosis provide superior quality cross-sectional images that allows doctor to make better decisions. In addition, surgical instruments have enhanced precision that improves the surgery success rates. Thus, availability of such upgraded ophthalmic devices and instruments have facilitated the diagnostic and surgical procedures that positively impacts the industry growth. However, complications and adverse reactions associated with the medications prescribed for minimizing the impact of diabetic retinopathy may hamper the industry growth to some extent.